New developments in lentiviral vector design, production and purification
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Lentiviruses are a very potent class of viral vectors for which there is presently a rapidly growing interest for a number of gene therapy. However, their construction, production and purification need to be performed according to state-of-the-art techniques in order to obtain sufficient quantities of high purity material of any usefulness and safety. AREAS COVERED: The recent advances in the field of recombinant lentivirus vector design, production and purification will be reviewed with an eye toward its utilization for gene therapy. Such a review should be helpful for the potential user of this technology. EXPERT OPINION: The principal hurdles toward the use of recombinant lentivirus as a gene therapy vector are the low titer at which it is produced as well as the difficulty to purify it at an acceptable level without degrading it. The recent advances in the bioproduction of this vector suggest these issues are about to be resolved, making the retrovirus gene therapy a mature technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 3×
“1 Calcium-phosphate precipitation The CaPO4 precipitation is traditionally used to produce LVV by transient transfection [13].”
BackgroundMethodA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“This has been achieved by replacing the U3 region of the 5¢ LTR by a strong tat-independent constitutive promoter [43].”
MethodA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The main advantage of this strategy is to avoid the oncogene activation risk caused by random LVV insertion in the genome [72,73].”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 3×
“For instance, these vectors have been used with success to generate IPS cells [185-187] and are promising tools for gene therapy [28,30].”
MethodLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 1×
“Engineered ZNFs has been coupled to NILV to be delivered to cells [82].”
MethodInduced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571 · cited 1×
“Although LVVs have shown distinct target site preferences [74] and less genotoxicity compared to g-RVVs [75], insertional mutagenesis risks still has to be considered when developing a clinical application [76].”
BackgroundChertova, E., Chertov, O., Coren, L. V., Roser, J. D., Trubey, C. M., Bess, J. W., Sowder, R. C., Barsov, E., Hood, B. L., Fisher, R. J., et al. (2006) · Journal of Virology · doi:10.1128/jvi.01013-06 · Cited by 462 · cited 1×
“Extensive studies have been performed to identify host proteins incorporated into wild type HIV-1 virions [177,178].”
BackgroundEffective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“The LVV DNA thus remains in the cell nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as the retina [69], brain [69,70] and muscle [71].”
BackgroundSomers, A., Jean, J.-C., Sommer, C. A., Omari, A., Ford, C. C., Mills, J. A., Ying, L., Sommer, A. G., Jean, J. M., Smith, B. W., et al. (2010) · Stem Cells · doi:10.1002/stem.495 · Cited by 423
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · cited 1×
“The LVV DNA thus remains in the cell nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as the retina [69], brain [69,70] and muscle [71].”
BackgroundDopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186 · cited 1×
“LVV are used to target several diseases such as adrenoleukodystrophy (ALD) [30], Parkinson’s disease [31], sickle cell anemia and b-thalassemia [32], cystic fibrosis [33], HIV [34] and cancer [35].”
MethodStable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · cited 1×
“The LVV DNA thus remains in the cell nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as the retina [69], brain [69,70] and muscle [71].”
BackgroundEpisomal vectors for gene expression in mammalian cells
Van Craenenbroeck, K., Vanhoenacker, P., & Haegeman, G. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01645.x · Cited by 147 · cited 8×
“It has been shown that 293T cells grow faster than their parental cell line and that vector productivity can be four times higher than with the parental cell line under the same conditions [87].”
BackgroundInfluentialHigashimoto, T., Urbinati, F., Perumbeti, A., Jiang, G., Zarzuela, A., Chang, L.-J., Kohn, D. B., & Malik, P. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302979 · Cited by 101 · cited 1×
“The woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) increases transgene expression in mammalian cells from different viral vectors [46,47] and the viral vector titer from transiently transfected 293T cells and stable producer cells by 7- to 15-fold, as compared to WPRE-lacking retroviral const…”
BackgroundHybrid Lentivirus-transposon Vectors with a Random Integration Profile in Human Cells
Staunstrup, N. H., Moldt, B., Mátés, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvák, Z., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.10 · Cited by 96
Cited by
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Current challenges in biotherapeutic particles manufacturing
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693541 · Cited by 123
“steps due to the high selectivity [33].”
Sources of Error in Mammalian Genetic Screens
Sack, L. M., Davoli, T., Xu, Q., Li, M. Z., & Elledge, S. J. (2016) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.030973 · Cited by 76
“A common source of such variation is the virus production method, in which excess plasmid is delivered to packaging cells during transfection, and is then carried over to target cells with viral supernatant during transduction (Segura et al. 2013).”
BackgroundMethodLentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
Metadata
- Authors
- Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-04-16
- Volume
- 13
- Issue
- 7
- Pages
- 987-1011
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2163096595
- Cited by
- 117
- References
- 20
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.